Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins

REFERENCES

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43–66.
   PubMed Web of Science ®Google Scholar
• Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010 (March 20);28(9):1467–72.
   PubMed Web of Science ®Google Scholar
• Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;60:2101–2103.
   PubMed Web of Science ®Google Scholar
• Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006;6:27.
   PubMed Web of Science ®Google Scholar
• Valsecchi ME, Pomerantz S, Jaslow R, Tester W. Reduced risk of bone metastasis for patients with breast cancer who used Cox-2 inhibitors. Clin Breast Cancer 2009;9(4):225–230.
   PubMed Web of Science ®Google Scholar
• Schmidt C. New studies support case for bisphosphonates as possible chemopreventive agent. J Natl Cancer Inst 2010;102(7): 453–455.
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R; ABCSG-12 Trial Investigators, Marth C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360(7):679–691.
   PubMed Web of Science ®Google Scholar
• Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005 (Feb);26(2):271–279.
   PubMed Web of Science ®Google Scholar
• Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002;294(2):441–447.
   Google Scholar
• Rhodes D, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE, Bhojani MS, Rehemtulla A, Kleer CG, Hayes DF, Lucas PC, Varambally S, Chinnaiyan AM. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. PNAS 2009;106(25):10284–10289.
   PubMed Web of Science ®Google Scholar
• Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest. 2002;82(6):747–756.
   PubMed Web of Science ®Google Scholar
• Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S, Kikkawa F. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 2005;11(7):2686–2694.
   PubMed Web of Science ®Google Scholar
• Ohnuma Y, Toda M, Fujita M, Hosono K, Suzuki T, Ogawa Y, Amano H, Kitasato H, Hayakawa K, Majima M. Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression. Biomed Pharmacother 2009;63(2):136–145.
   PubMed Web of Science ®Google Scholar
• Otake AH, Mattar AL, Freitas HC, Machado CM, Nonogaki S, Fujihara CK, Zatz R, Chammas R. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Cancer Chemother Pharmacol 2010;66(1):79–87.
   PubMed Web of Science ®Google Scholar
• Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens 2009;23(10):623–635. Epub Apr 2, 2009.
   PubMed Web of Science ®Google Scholar
• Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA. VATTC Trial: Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst. 2008;100(17): 1223–1232.
   PubMed Web of Science ®Google Scholar
• Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet 1997; 349(9051):525–528.
   PubMed Web of Science ®Google Scholar
• Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998;352(9123):179–184.
   PubMed Web of Science ®Google Scholar
• Lang L. ACE inhibitors may reduce esophageal cancer incidence. Gastroenterology 2006;131(2):343–344.
   Web of Science ®Google Scholar
• Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing 1st-line platinum-based chemotherapy. J Cancer Res Clin Oncol 2009;135: 1429–1435.
   PubMed Web of Science ®Google Scholar
• Friis S, Sørensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, Olsen JH. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001;92(9):2462–2470.
   PubMed Web of Science ®Google Scholar
• Coleman C, Baker W, Kluger J, White CM. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens 2008;26(4):622–629.
   PubMed Web of Science ®Google Scholar
• Meier C, Derby L, Jick S, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000;160(3):349–353.
   PubMed Web of Science ®Google Scholar
• Koomen E, Herings R, Guchelaar H, Nijsten T. Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cancer Epidemiol 2009;33(5):391–395.
   PubMed Web of Science ®Google Scholar
• Chan K, Oza A, Siu L. The statins as anticancer agents. Clin Cancer Res 2003;9:10–19.
   PubMed Web of Science ®Google Scholar
• Muck AO, Seeger H, Wallwiener D (2004) Inhibitory effect of statins on the proliferation of human breast cancer cells. Int J Clin Pharmacol Ther 42:695–700.
   PubMed Web of Science ®Google Scholar
• Keyomarsi, K., Sandoval, L, Band, V, and Pardee, AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991;51:3602–3609.
   PubMed Web of Science ®Google Scholar
• Agarwal, B, Bhendwal, S, Halmos, B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999;5:2223–2229.
   PubMed Web of Science ®Google Scholar
• Denoyelle, C, Vasse, M, Korner, M, Mishal Z, Ganné F, Vannier JP, Soria J, Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis (Lond.) 2001;22: 1139–1148.
   PubMed Web of Science ®Google Scholar
• Graaf M, Richel D, van Noorden C, Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004;30:609–641.
   PubMed Web of Science ®Google Scholar
• Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2000;10:143–148.
   PubMed Web of Science ®Google Scholar
• Kotamraju S, Willams C, Kalyanaraman B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res 2007;67(15):7386–7394.
   PubMed Web of Science ®Google Scholar
• Åberg M, Wickström M, Siegbahn A. Simvastatin induces apoptosis in human breast cancer cells in a NFκB dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa. Thromb Res 2008;122:191–202.
   PubMed Web of Science ®Google Scholar
• Koyuturk M, Ersoz M, Altiok N. Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett 2007;250:220–228.
   PubMed Web of Science ®Google Scholar
• Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC. Breast cancer growth prevention by statins. Cancer Res 2006;66:8707–8714.
   PubMed Web of Science ®Google Scholar
• Kumar AS, Benz C, Shim V, Minami CA, Moore DH, Esserman LJ. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev 2008;17(5):1028–1033.
   PubMed Web of Science ®Google Scholar
• Beck P, Wysowski DK, Downey W, Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol 2003;56(3):280– 285.
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 2004;100(11): 2308–2316.
   PubMed Web of Science ®Google Scholar
• Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004; 22(12):2388–2394.
   PubMed Web of Science ®Google Scholar
• Kaye JA, Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer 2004;90(3):635–637.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005;23(34):8606–8612.
   PubMed Web of Science ®Google Scholar
• Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 2005;165(19):2264–2271.
   PubMed Web of Science ®Google Scholar
• Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg CD, Chlebowski RT, Women's Health Initiative Research Group. Statin use and breast cancer: prospective results from the Womens Health Initiative. J Natl Cancer Inst 2006;98(10):700–707.
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 2007;16(3):416–421.
   PubMed Web of Science ®Google Scholar
• Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007;115:27–33.
   PubMed Web of Science ®Google Scholar
• Pocobelli G, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Egan KM. Statin use and risk of breast cancer. Cancer 2008;112:27–33.
   PubMed Web of Science ®Google Scholar
• Kwan M, Habel LA, Dawn Flick E, Quesenberry CP, Caan B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 2008;109:573–579.
   PubMed Web of Science ®Google Scholar
• Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Revision of the American joint committee on cancer staging system for breast cancer. J Clin Oncol 2002;20:3628–3636.
   PubMed Web of Science ®Google Scholar
• Koh WP, Yuan JM, Sun CL, van den Berg D, Seow A, Lee HP, Yu MC. ACE gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res 2003;63:573–578.
   PubMed Web of Science ®Google Scholar
• Koh WP, Yuan JM, van den Berg D, Seow A, Lee HP, Yu MC. Polymorphisms in angiontensin II type 1 receptor and ACE genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis 2005;26:459–464.
   PubMed Web of Science ®Google Scholar
• González-Zuloeta Ladd AM, Arias Vásquez A, Sayed-Tabatabaei FA, Coebergh JW, Hofman A, Njajou O, Stricker B, van Duijn C. Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14(9):2143–2146.
   PubMed Web of Science ®Google Scholar
• Yaren A, Turgut S, Kursunluoglu R, Oztop I, Turgut G, Degirmencioglu S, Kelten C, Erdem E. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients with breast cancer and effects on prognostic factors. J Investig Med 2007;55(5):255–261.
   PubMed Web of Science ®Google Scholar